Dexamethasone
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Dexamethasone: From Established Glucocorticoid Use to Alopecia Areata
One-Sentence Summary
Dexamethasone is a potent synthetic glucocorticoid. The supplied data do not state its original approved indication. The TxGNN model predicts it may be effective for Alopecia Areata. The literature supports this direction (about 13 of 20 publications directly address dexamethasone or systemic steroids in this condition, including 1 small RCT and 1 network meta-analysis). None of the 14 retrieved clinical trials studies alopecia areata.
Quick Overview
| Item | Content |
|---|---|
| Predicted New Indication | Alopecia areata |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L3 (observational studies and systematic review; see note below) |
| South Africa Market Status | Marketed |
| Number of SAHPRA Registrations | 9 |
| Recommended Decision | Proceed with Guardrails |
Note: The pack’s automated scoring assigned L2. I rated it L3 because the only RCT (PMID 36086930) is a small, open-label, single-centre study of 30 children. It is not a registered Phase 2/3 trial, and no registered trial addresses this indication.
Why is This Prediction Reasonable?
Detailed mechanism-of-action data is not available in the supplied dataset. The rationale below rests on general glucocorticoid pharmacology and the published literature, not on the supplied metadata.
Alopecia areata is an autoimmune, T-cell-mediated attack on hair follicles. Dexamethasone’s anti-inflammatory and immunosuppressive actions can plausibly dampen this attack and help restore the follicle’s immune privilege.
The clinical literature is consistent with this. Oral and intravenous dexamethasone “mini-pulse” regimens have been used for decades in extensive and severe alopecia areata, in both adults and children. A 2024 network meta-analysis compared systemic steroids with JAK inhibitors and contact immunotherapy. Recent reports also describe dexamethasone as an option where JAK inhibitors are unavailable or unsuitable.
Clinical Trial Evidence
Fourteen registered trials were retrieved, but none studies alopecia areata. Most are oncology studies in which dexamethasone is a backbone drug, and two are unrelated to hair loss. No ICTRP, SANCTR or PACTR entries were found. The five most closely related to dexamethasone are shown for transparency:
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT02288078 | Phase 2 | Unknown | 74 | Prophylactic dexamethasone for regorafenib-related fatigue in colorectal cancer (not hair loss) |
| NCT02004275 | Phase 1/2 | Unknown | 118 | Pomalidomide, dexamethasone ± ixazomib in multiple myeloma |
| NCT02685826 | Phase 1/2 | Completed | 56 | Durvalumab + lenalidomide ± dexamethasone in newly diagnosed myeloma |
| NCT02773030 | Phase 1/2 | Active, not recruiting | 466 | CC-220 with dexamethasone-based combinations in multiple myeloma |
| NCT04343560 | N/A | Completed | 380 | Dexamethasone suppression test used in adrenal adenoma and bone-strength study |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 36086930 | 2022 | RCT | Dermatol Ther | Open-label, 30 children with severe non-progressive AA: dexamethasone oral mini-pulse vs DPCP contact sensitisation |
| 39042154 | 2024 | Systematic review / network meta-analysis | Arch Dermatol Res | Compares systemic steroids, oral JAK inhibitors and contact immunotherapy in severe AA |
| 36461625 | 2023 | Review | Pediatr Dermatol | Dosing regimens and side effects of pulse corticosteroids in paediatric AA |
| 35330017 | 2022 | Prospective cohort | J Clin Med | Real-world effectiveness, safety and response factors of oral mini-pulse treatment |
| 36070222 | 2022 | Multicentre study | Dermatol Ther | Oral dexamethasone mini-pulse in moderate to severe AA |
| 31579982 | 2019 | Cohort | Dermatol Ther | 73 children with severe AA: 1-day vs 3-day IV dexamethasone pulses plus topical clobetasol |
| 26179196 | 2015 | Long-term cohort | Dermatol Ther | 65 children with severe AA: monthly oral dexamethasone pulse plus topical steroid, median follow-up 96 months |
| 16707886 | 2006 | Comparative study | Dermatology | Efficacy, relapse rate and side effects of three systemic corticosteroid regimens |
| 10535249 | 1999 | Clinical series | J Dermatol | 30 patients with extensive AA: 5 mg dexamethasone oral pulse on two consecutive days weekly |
| 41243342 | 2025 | Case report with focused review | J Dermatol Treat | Durable remission of severe AA with oral mini-pulse where JAK inhibitors were not an option |
South Africa Market Information
Nine registrations are on record. Five are shown below, and manufacturer and approved-indication text are not populated in the source data.
| Registration Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| A40/21.5.1/0748 | Fresenius dexamethasone ampoule 1ml | Injection | Not stated in dataset |
| 33/21.5.1/0512 | Pharma-q dexamethasone phosphate ampoule | Injection | Not stated in dataset |
| 49/16.2/0071 | Xindex | Drops | Not stated in dataset |
| 49/15.3/0196 | Mydex | Drops | Not stated in dataset |
| H1482 (ACT 101 1965) | Sofradex 8ml | “Eed” (as recorded) | Not stated in dataset |
The listed forms are injectable, drops and eye ointment. The supplied data show no oral dexamethasone product, yet the published mini-pulse regimens are mostly oral. Check whether an oral product is registered among the four registrations not shown.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Published evidence for dexamethasone in alopecia areata is consistent and clinically plausible. It includes one small RCT, a network meta-analysis and several cohorts. However, it comes mostly from observational and paediatric studies, and there are no registered trials in this indication. The safety data from the SAHPRA package insert are missing (flagged as blocking), so any use should stay within guardrails.
To proceed, the following is needed:
- SAHPRA package insert warnings and contraindications (blocking data gap), obtained by downloading and parsing the PI
- Mechanism-of-action data, via DrugBank
- Confirmation of which registered SA products (particularly oral forms) suit pulse regimens
- Clinician review of relapse risk after stopping and of long-term steroid toxicity. Steroid response is reported to be poor in the universalis form (rank 9 below).
- Confirmation of the original approved indication, which is empty in the current dataset
Other predicted indications (ranks 2–10): All are prediction-only (L5, Hold), with no supporting trials or literature. Two retrieved papers are unrelated to dexamethasone efficacy, one a myeloma skin-toxicity review and one an ICU symposium abstract set. Ranks 3 and 8–10 (telogen effluvium, atrichia with papular lesions, prolapse of lacrimal gland) have no plausible glucocorticoid mechanism and are likely knowledge-graph artefacts.
This report is for research reference only and does not constitute medical advice. Predicted repurposing candidates require clinical validation before use.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.